Skip to main content
SpringerLink
Log in

Mayday for Dual PPAR Agonists

Once-Hyped Diabetes Therapies in Their Death Throes?

  • Emerging Technology
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294 (20): 2581–6

    Article  PubMed  CAS  Google Scholar 

  2. Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006; 29: 1016–23

    Article  PubMed  CAS  Google Scholar 

  3. Nissen SE. Adverse events related to muraglitazar use in diabetes: reply. JAMA 2006; 295 (17): 1998

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mayday for Dual PPAR Agonists. Pharmaceutical & Diagnostic Innovation 4, 7–10 (2006). https://doi.org/10.1007/BF03257079

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03257079

Keywords

Search

Navigation